Hepatic Perfusion Treatment Improves Survival and Shrinks CRC Liver Tumors

Colorectal cancer patients whose cancer had spread to their livers benefited from surgery during which heated chemotherapy was pumped directly to their livers. Isolated hepatic perfusion (IHP) shrank tumors and increased survival time.  It may be a hopeful new approach to treating colorectal cancer that is widespread in the liver. Median survival time after the treatment…  Read More

Response to Chemo Before Liver Met Resection Doesn't Predict Survival

Patients who had tumors shrink in response to chemotherapy given before they had surgery for colorectal cancer that had spread to their livers had no better long-term survival than patients whose cancer remained the same or even got worse. Doctors in New York followed 111 patients who had chemotherapy before surgery to remove liver metastases (neoadjuvant…  Read More

Liver Symposium Brings Survivors and Health Pros Together

The Liver Symposium will bring together patients and health care providers at the Palmer House in Chicago on May 15 and 16 in a unique collaboration of contining medical education and cancer survivor input to share the latest information about managing liver tumors. Sponsored by YES, a grassroots organization of liver tumor survivors dedicated to helping patients…  Read More

Stereotactic Body Radiotherapy for Liver Mets Safe

An early clinical trial of focused radiation therapy for liver metastases appeared to be safe without causing liver disease. Stereotactic body radiotherapy (SBRT) delivers high doses of radiation to a carefully targeted area of the body.  Its goal is to destroy cancer cells while leaving healthy tissue unharmed. Radiation oncologists at Princesss Margaret Hospital at the…  Read More

Survival of Medicare Patients after Surgery for Liver Mets

While some surgical studies are now reporting five-year survival after surgery to remove colorectal cancer tumors that have spread to the liver of 40 to 60 percent, a review of more general national experience for patients enrolled in Medicare  in the United States found lower survival rates. Among Medicare-enrolled colorectal cancer patients 65 and over who…  Read More

Chemotherapy with Erbitux Converts Unresectable Liver Mets to Allow Surgery

Update from the 2009 Gastrointestinal Cancer Symposium Combining chemotherapy with Erbitux® (cetuximab) can effectively shrink tumors and enable surgeons to remove formerly unresectable colorectal cancer that has spread to the liver, offering potentially curative treatment.